
Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis
<a href="https://news.google.com/rss/articles/CBMioAJBVV95cUxPWENKemc4bjhneW8wM0pfMkRMWV84YXJCR0pUT3U3YVB5aFdRb1ExRlBXVmZUVUdjaGlsSjR3U2VBaTZJZlBNaWNSRjRud0thS1pGNGlia3ZTeXpCUmlQS2hHdGg1TDRJNTN4aDg2bUlNa2NiZ3FrbjBjdGRuVGtocWVUWjdseURJUjhHX1cwNXRxOW1fYTJuNXN2ZXdENkpObm5OSW55WGd1NV9BNUp5ckh0Wl9neVRabFBvNlFVNk42OFNGRG9LR1RFYW1KUzVaZVZJVklEZnMtUlpfaG5zRTNaV21hckdUMnBtT1dRcEhHYV94WENOMTlsRjBScGJkNkp0MS1KSGhBYmh4OERsWkZucVRXelVVZmxMVlhjTV8?oc=5" target="_blank">Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
